| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.039 | 0.9 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.036 | 0.9 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |